Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

34.13 -0.20 (-0.58%)
Official Closing Price Updated: 5:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
35 36 Next >
GSK Transfers Cell Therapy Program Rights To Adaptimmune, Terminates Second Cell Therapy Pact In A Day
Via Benzinga
GSK Walks Away From T-Cell Therapy Pact With Lyell Citing Strategic Actions
Via Benzinga
GSK Plc (NYSE:GSK) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 10/21/2022 -- An investigation was announced on behalf of investors in NYSE:GSK shares over potential breaches of fiduciary duties by certain officers and directors at GSK... 
Via SBWire
Children's Hospitals Strained After Climbing Cases In Respiratory Illnesses In Kids
Physicians are reporting a sharp increase in cases of the respiratory syncytial virus (RSV), creating capacity issues in several children's hospitals in the U.S. before the typically busier winter... 
Via Benzinga
Peering Into GSK's Recent Short Interest
GSK's (NYSE:GSK) short percent of float has risen 12.86% since its last report. The company recently reported that it has 15.83 million shares sold short, which is 0.79% of all regular shares that are... 
Via Benzinga
Boston University's COVID-19 Created In Lab Research Comes Under Scrutiny
Boston University created an artificial form of COVID-19 in a laboratory. Now, U.S. health officials have launched an inquiry into a controversial study. The Boston University research was designed to... 
Via Benzinga
3 Things the Smartest Investors Know About This Beaten-Down Stock
Moderna's story may just be beginning. 
Via The Motley Fool
FDA Approves GSK's Whooping Cough Vaccine During Pregnancy For Prevention In Infants
Via Benzinga
7 Quality Stocks Selling at a Discount as Q4 Kicks Off
Stocks may have just entered a bull market, so bullish investors should look for quality stocks selling at a discount to buy before a rally. 
Via InvestorPlace
This Addiction Drug Shows Some Potential Against Long COVID Symptoms
Researchers are working on cures for long COVID. With some success, naltrexone has been used to treat pain, fatigue, and brain fog months after a coronavirus infection. 
Via Benzinga
Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm'
Via Benzinga
Oil Output Cut May Tip Global Economy Into Recession, Elon Musk's Starship's First Space Tourist, Alphabet Approves Distribution Of Trump's Truth Social App: Top Stories Thursday, Oct. 13
Reuters 
Via Benzinga
Unilever CEO Alan Jope To Retire Next Year
Via Benzinga
GSK Touts 'Exceptional Results' From RSV Vaccine Candidate In Older Adults
Via Benzinga
Is Pfizer Stock Still Worth Buying After the Pandemic?
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations. 
Via MarketBeat
Exposures COVID-19
Want $1,000 in Passive Income? Don't Make These 3 Mistakes
It's easy to get poor returns if you don't diversify your portfolio and carefully calibrate your expectations. 
Via The Motley Fool
3 Dirt-Cheap Stocks That Could Soar 48% to 68%, According to Wall Street
These stocks could attract both value and growth investors. 
Via The Motley Fool
AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial
Via Benzinga
DEA-Licensed Pharmaceutical Cannabis Research Company Announces $20M Series A Funding Round
The Biopharmaceutical Research Company (BRC), an active DEA pharmaceutical cannabis license holder, announced the completion of a $20 million Series A fundraise, that will enable the company to scale... 
Via Benzinga
The Next Pandemic? Vir Biotechnology Just Signed A $1 Billion Deal To Work On It
BARDA will pay Vir up to $1 billion to develop its experimental treatment. 
Via Investor's Business Daily
This Is the Best Time to Buy These 7 Long-Term Dividend Stocks
Investors want long-term dividend stocks to buy as interest rates rise. 
Via InvestorPlace
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
7 Consumer Stocks to Sell Before They Die
These are the top consumer stocks to sell before things get worse. These companies are struggling with issues that will take years to fix. 
Via InvestorPlace
2 High Yielders Decimated By The Russia-Ukraine War: Is Now The Time To Buy?
As the Russia-Ukraine war moves forward, the European economy remains in a fragile state. 
Via Benzinga
iPhone 14 Popular In China?, Netflix May Lose Comics, Elon Musk's Starlink Slows, Byron Allen Faces $10B Lawsuit And More Top Financial Media Stories Monday, Sept. 26
Bloomberg 
Via Benzinga
Burberry Finance Chief Joins GSK As First Woman CFO
Via Benzinga
7 Stocks to Buy That Can Soar in Good Times or in Bad
Investors looking for growth stocks to buy that are largely immune from broader economic woes have come to the right place. 
Via InvestorPlace
Spero Therapeutics (NASDAQ: SPRO) Enters into Exclusive Licensing Agreement with GSK (NYSE: GSK) for the Commercialization of Tebipenem HBr
Spero Therapeutics, Inc. (NASDAQ: SPRO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and 
Via Spotlight Growth
Exposures Product Safety
Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement
Spero Therapeutics (SPRO) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (GSK). 
Via InvestorPlace
Top Financial Media Stories Thursday, September 22: Facebook Sued For Bypassing Apple Privacy Rules, Walmart Slows Hiring Plans Ahead Of Holiday Season, China Blames US For Northwestern Polytechnical University Hack And More..
Reuters 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.